Search Results



Your search for all items matches 230 pages

Showing 151 - 200


hematologic malignancies

Siltuximab for Multicentric Castleman’s Disease

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On April 23, 2014, the anti–interleukin (IL)-6 monoclonal antibody ...

solid tumors
hematologic malignancies

ASPHO Abstracts Cover Broad Range of Topics

More than 400 abstracts—a record—were submitted for the 27th Annual Meeting of the American Society of Pediatric Hematology/Oncology in Chicago. Here is a small sampling of those studies, with comments from the abstract authors. Token Economy to Improve Compliance BMT Bucks form the basis of a...

hematologic malignancies

FDA Grants Fast Track Designation to Novel JAK2 Inhibitor for the Treatment of Myelofibrosis

The U.S. Food and Drug Administration has granted Fast Track designation to pacritinib for the treatment of intermediate- and high-risk myelofibrosis, including patients with disease-related thrombocytopenia on other JAK2 therapy or patients who are intolerant to or whose symptoms are suboptimally...

hematologic malignancies

‘Paradigm-Shifting’ Results in Treatment of Hematologic Disorders

The three leukemia/lymphoma studies selected from the many 2014 ASCO Annual Meeting abstracts for presentation at the recent Best of ASCO meeting in Chicago “are really paradigm-shifting,” noted Lucy A. Godley, MD, PhD, of the University of Chicago. These studies, she said, “give great promise for...

hematologic malignancies

Louis J. DeGennaro, PhD, Named President and Chief Executive Officer of The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society has announced that Louis J. DeGennaro, PhD, has been appointed as President and Chief Executive Officer, effective immediately. “Dr. DeGennaro has tirelessly dedicated himself for almost a decade of service to the Leukemia & Lymphoma Society mission and to...

hematologic malignancies
solid tumors
issues in oncology

Top 10 Myths About FDA’s Office of Hematology and Oncology Products

INSIDE THE BLACK BOX is an occasional column providing insight into the U.S. Food and Drug Administration (FDA) and its policies and procedures. In this installment, FDA oncologists Gideon Blumenthal, MD, and Tatiana Prowell, MD, discuss 10 common myths about FDA’s Office of Hematology and Oncology ...

hematologic malignancies

The American Society of Hematology Elects New Leadership

The American Society of Hematology (ASH) recently announced the election of four new members to its Executive Committee, the governing body of the organization, for terms beginning after the 2014 ASH Annual Meeting, which will be held December 6–9 in San Francisco. Kenneth C. Anderson, MD, will...

hematologic malignancies
global cancer care

ASH Pairs Hematologists From Developing and Developed Nations for Global Training Program

The American Society of Hematology (ASH) recently announced the 20 hematologists and other medical professionals selected to participate in the 2014 ASH Visitor Training Program. This program provides talented hematologists, scientists, and laboratory staff from developing countries the opportunity ...

hematologic malignancies

ASH Honors Senator Barbara Mikulski and Patient Advocate Kathy Giusti

The American Society of Hematology (ASH) recognized Senator Barbara Mikulski (D-MD) and Kathy Giusti, Founder of the Multiple Myeloma Research Foundation, with awards for their outstanding support and advocacy for biomedical research and the practice of hematology at the 56th ASH Annual Meeting in...

hematologic malignancies

FDA Approves Ruxolitinib to Treat Patients With Polycythemia Vera

The U.S. Food and Drug Administration (FDA) approved a new use for ruxolitinib (Jakafi) to treat patients with polycythemia vera, a chronic type of bone marrow disease. Ruxolitinib, a JAK inhibitor, is the first drug approved by the FDA for this condition. Polycythemia vera occurs when too many...

hematologic malignancies

ASH Releases Second List for Choosing Wisely Campaign

The American Society of Hematology (ASH) has announced five additional commonly used tests, treatments, and procedures in hematology that physicians and patients should question in certain circumstances. The additional items join an initial list of five practices to question that the Society...

hematologic malignancies
solid tumors

Clinical Trials Actively Recruiting Children and Young Adults With Cancer

The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies of children and young adult cancer survivors. The studies include phase I, I/II, III, observational, and interventional trials investigating genomic profiling to personalize treatment;...

hematologic malignancies

Will Checkpoint Inhibitors Be Winners in Hematologic Cancers, Too?

A  “Featured Topic” session during the 56th American Society of Hematology (ASH) Annual Meeting and Exposition drew a standing-room-only crowd to hear two experts weigh in on checkpoint blockade in hematologic malignancies. While new to hematology, these drugs—the cytotoxic T-lymphocyte–associated...

solid tumors
hematologic malignancies

FDA Drug Approvals 2014

Nivolumab (Opdivo), a monoclonal antibody, was approved for treatment of metastatic melanoma.  Approved December 22, 2014. Olaparib (Lynparza), a poly (ADP-ribose) polymerase (PARP) inhibitor, was approved for treatment of BRCA-mutated advanced ovarian cancer. Approved December 19, 2014....

hematologic malignancies
leukemia

New Choosing Wisely List, Leukemia Quick-Takes From ASH

Nearly 5,000 scientific abstracts were presented at the 2014 American Society of Hematology (ASH) Annual Meeting and Exhibition in San Francisco. Along with our targeted coverage of the meeting’s key newsmakers, The ASCO Post provides you with these brief reports of other interesting...

hematologic malignancies

Ibrutinib for Waldenström’s Macroglobulinemia

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On January 29, 2015, the U.S. Food and Drug Administration...

hematologic malignancies

Two Case Reports on the Evaluation of Myeloid Neoplasm

The ASCO Post is pleased to introduce “Hematology Expert Review,” a new feature including a case report detailing a particular hematologic condition followed by questions. Answers to each question appear with expert commentary. In this first installment, we present two cases of older men with...

hematologic malignancies

The Current State of Hematologic Malignancies

Due in part to the refinement of bone marrow transplantation and its many innovations, some leukemias that once were death sentences now have cure rates of up to 90%. As research in transplantation and other promising areas accelerates, we are on the verge of breaking new clinical boundaries in...

hematologic malignancies

Clonal Hematopoiesis With Somatic Mutations Increases Risk of Hematologic Cancer, Mortality, and Cardiovascular Disease

In two studies recently reported in The New England Journal of Medicine,1,2 whole-exome sequencing of DNA from peripheral blood cells of individuals unselected for hematologic phenotype showed that clonal hematopoiesis with somatic mutations is increasingly common with increasing age and is...

hematologic malignancies

Microangiopathic Hemolytic Anemia and Thrombocytopenia

The ASCO Post is pleased to present Hematology Expert Review, an occasional feature that includes a case report detailing a particular hematologic condition followed by questions. Answers to each question with expert commentary can be found in the sidebar. In this installment, we present the case...

hematologic malignancies

ASH Announces Top Trainee Abstracts of 2015 Annual Meeting

The American Society of Hematology (ASH) recognized investigators with the highest-scoring abstracts in the categories of undergraduate student, medical student, graduate student, resident physician, and postdoctoral fellow at the 57th ASH Annual Meeting and Exhibition, December 5–8 in Orlando,...

hematologic malignancies
leukemia
lymphoma

Adding Ibrutinib to Bendamustine/Rituximab Increases Progression-Free Survival in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

In the phase III HELIOS trial, reported in The Lancet Oncology, Chanan-Khan et al found that adding the Bruton’s tyrosine kinase inhibitor ibrutinib (Imbruvica) to bendamustine (Treanda)/rituximab (Rituxan) increased progression-free survival in patients with chronic lymphocytic leukemia or...

hematologic malignancies
leukemia
issues in oncology
issues in oncology

Germline ETV6 Variations as Basis of Novel Genetic Syndrome Associated With Childhood Acute Lymphoblastic Leukemia

In a systematic genetic study reported in The Lancet Oncology, Moriyama et al found that germline ETV6 variations identified in a small proportion of children with acute lymphoblastic leukemia (ALL) were associated with a novel syndrome predisposing carriers to disease. Recent data indicated that...

hematologic malignancies
leukemia
lymphoma
lymphoma

ASH 2015: High Response Rates, Long-Term Remissions in Relapsed/Refractory Pediatric ALL, Lymphomas After CTL019 Immunotherapy

Ninety-three percent of pediatric patients (55 of 59) with relapsed/refractory acute lymphoblastic leukemia (ALL) went into remission after receiving an investigational therapy made from their own immune cells, with continuous remissions of over 1 year in 18 patients and over 2 years in nine...

hematologic malignancies

Reduced Nonrelapse Mortality With Busulfan/Fludarabine vs Busulfan/Cyclophosphamide for Stem Cell Transplantation in Acute Myeloid Leukemia

In a phase III trial reported in The Lancet Oncology, Rambaldi et al found that a myeloablative conditioning regimen of busulfan/fludarabine was associated with reduced nonrelapse mortality vs busulfan/cyclophosphamide in patients with acute myeloid leukemia (AML) undergoing allogeneic...

hematologic malignancies
issues in oncology

ASH 2015: American Society of Hematology Releases Compilation of Top Choosing Wisely Recommendations Relevant to Hematology

The American Society of Hematology (ASH) has released a list of five hematology-related tests and procedures to question based on recommendations from other medical societies taking part in the American Board of Internal Medicine (ABIM) Foundation’s Choosing Wisely® campaign. This list...

hematologic malignancies
multiple myeloma

Study Finds Better Outcome With Melphalan Plus ASCT vs Chemotherapy Plus Lenalidomide Consolidation in Multiple Myeloma

In a phase III trial reported in The Lancet Oncology, Gay et al found that progression-free survival was shorter with lenalidomide (Revlimid) plus chemotherapy vs high-dose melphalan plus autologous stem cell transplantation in transplant-eligible patients with multiple myeloma, with no significant ...

hematologic malignancies
lymphoma

Prognostic Model for Survival in Advanced-Stage Mycosis Fungoides and Sézary Syndrome

As reported by Scarisbrick et al in the Journal of Clinical Oncology, a Cutaneous Lymphoma International Consortium study in a large population of patients with advanced-stage mycosis fungoides and Sézary syndrome has identified independent prognostic factors for overall survival that can be ...

hematologic malignancies
leukemia

German Phase II Trial Shows Benefit and Increased Toxicity With Addition of Sorafenib to Standard Therapy in Newly Diagnosed AML

In a German phase II trial reported in The Lancet Oncology, Röllig et al found that the addition of sorafenib (Nexavar) to standard therapy improved event-free survival but increased toxicity vs placebo in patients aged ≤ 60 years with newly diagnosed acute myeloid leukemia (AML). Study...

hematologic malignancies
myelodysplastic syndromes

Self-Reported Fatigue Provides Independent Prognostic Information in Patients With Myelodysplastic Syndromes

In a prospective observational cohort study reported in The Lancet Oncology, Efficace et al found that a self-reported fatigue score provides independent prognostic information on overall survival in patients with higher-risk myelodysplastic syndromes. Fatigue assessment should be included in...

hematologic malignancies
leukemia
lymphoma
issues in oncology

Half-Matched Bone Marrow Transplant Recipients May Tolerate Transplantation Just as Well as Fully Matched Recipients

Bone marrow transplantation is a lifesaving therapy for many patients with blood cancers like leukemias and lymphomas. Currently, the gold standard blood-generating stem cells are obtained from a donor, most likely a sibling, with a perfect match to the patient in order to minimize the chance of...

hematologic malignancies

Telomerase Inhibitor Imetelstat Shows Activity in Myelofibrosis

In a pilot study reported in The New England Journal of Medicine, Tefferi et al found that imetelstat, which targets the RNA template of telomerase reverse transcriptase, produced responses in patients with myelofibrosis. Treatment was associated with myelosuppression in some patients. Current...

hematologic malignancies

Nonmyeloablative Transplantation With High-Dose Cyclophosphamide May Improve Outcomes in Older Patients With Hematologic Malignancy

 In a recent report of single-institution experience in the Journal of Clinical Oncology, Kasamon et al found that nonmyeloablative-related HLA-haploidentical blood or marrow transplantation (BMT) followed by high-dose cyclophosphamide produced good outcomes in patients aged 50 to 75 years...

hematologic malignancies
lymphoma

Investigational Topical Gel Is Safe and Effective in Patients With Cutaneous T-Cell Lymphoma, Phase I Trial Shows

Results of a phase I trial show that an investigational topical drug, resiquimod gel, causes regression of both treated and untreated tumor lesions and may completely remove cancerous cells from both sites in patients with early-stage cutaneous T-cell lymphoma. Currently, there is no cure for...

hematologic malignancies
lymphoma

Early Relapse of Follicular Lymphoma After R‑CHOP Associated With Increased Mortality

In an analysis from the National LymphoCare Study reported in the Journal of Clinical Oncology, Casulo et al found that disease progression within 2 years of diagnosis was associated with increased mortality risk after first-line R-CHOP (rituximab [Rituxan] plus cyclophosphamide, doxorubicin,...

health-care policy
hematologic malignancies
leukemia
issues in oncology
issues in oncology
cost of care

Study Finds Current Prices of Hematologic Cancer Drugs Are Not Justified

The costs associated with cancer drug prices have risen dramatically over the past 15 years, a trend concerning to many oncologists. In a new analysis, researchers at The University of Texas MD Anderson Cancer Center concluded that the majority of existing treatments for hematologic cancers are...

hematologic malignancies
leukemia
issues in oncology

Importance of Establishing Definitions to Increase Survival After Blood/Marrow Transplant

Blood and marrow transplantation is a potentially curative treatment for patients with leukemia or other life-threating blood diseases. With a goal of increasing survival rates, a research team led by Roswell Park Cancer Institute (RPCI) investigators verified patient outcome data submitted by more ...

hematologic malignancies
hepatobiliary cancer
pancreatic cancer
issues in oncology

Abdominal Blood Clots May Indicate Undiagnosed Cancer

New research published by Søgaard et al in Blood found that blood clots in the abdominal veins might be an indicator of undiagnosed cancer. The study also suggests that these clots predict poorer survival in patients with liver and pancreatic cancer. Clotting and Cancer Risk Compared to...

hematologic malignancies
issues in oncology

ASCO 2015: JAK Inhibitor Pacritinib Proves Effective for Easing Symptoms of Myelofibrosis

Findings from the PERSIST-1 study of patients with myelofibrosis show that the JAK inhibitor pacritinib is significantly more effective than best available therapy, which includes a range of off-label treatments, for easing the symptoms of myelofibrosis. At a landmark analysis at 24 weeks of...

hematologic malignancies
leukemia
multiple myeloma
lymphoma

Study Links Paternal Age to Child’s Risk of Developing Blood and Immune System Cancer in Adulthood

A new study links a father's age at birth to the risk that his child will develop blood and immune system cancers as an adult, particularly for only children. The study, published by Teras et al in the American Journal of Epidemiology, found no association between having an older mother and these...

hematologic malignancies
leukemia

AACR 2015: New T Cell–Based Immunotherapy Shows Promise for Lethal Stem Cell Transplant Complication

More than 60% of patients with Epstein-Barr virus–associated lymphoproliferative disorder (EBV-LPD) that was nonresponsive to standard rituximab (Rituxan) treatment responded to a new type of immunotherapy called Epstein-Barr virus–specific cytotoxic T-lymphocyte (EBV-CTL) therapy....

hematologic malignancies

Ibrutinib Is Highly Active in Previously Treated Waldenström’s Macroglobulinemia

In a study reported in The New England Journal of Medicine, Treon et al found that ibrutinib (Imbruvica) was highly active and produced durable responses in patients with previously treated Waldenström’s macroglobulinemia. Response rates were highest in patients with MYD88 mutation and...

hematologic malignancies

Translocation t(11;14) Associated With Poorer Outcome in Bortezomib-Treated Newly Diagnosed Amyloid Light-Chain Amyloidosis

In a single-institution study reported in the Journal of Clinical Oncology, Bochtler et al found that presence of the t(11;14) translocation on interphase fluorescence in situ hybridization (iFISH) was associated with poorer hematologic event-free and overall survival in patients receiving...

hematologic malignancies

Ruxolitinib Better Than Standard Therapy in Polycythemia Vera Patients With Inadequate Response to or Intolerance of Hydroxyurea

In a phase III trial reported in The New England Journal of Medicine, Vannucchi et al found that the JAK1/JAK2 inhibitor ruxolitinib (Jakafi) produced significantly better hematocrit control and reduction in spleen volume than standard treatment in patients with polycythemia vera with inadequate...

hematologic malignancies
issues in oncology

Clonal Hematopoiesis With Somatic Mutations Increases With Age and Increases Risk of Hematologic Cancer and Mortality

In a study reported in The New England Journal of Medicine, Genovese et al found that clonal hematopoiesis with somatic mutations is increasingly common with greater age and is associated with increased risk of hematologic cancer. The presence of such clonal hematopoiesis in apparently healthy...

hematologic malignancies

FDA Approves Ruxolitinib to Treat Patients With Polycythemia Vera

The U.S. Food and Drug Administration (FDA) today approved a new use for ruxolitinib (Jakafi) to treat patients with polycythemia vera, a chronic type of bone marrow disease. Ruxolitinib, a JAK inhibitor, is the first drug approved by the FDA for this condition. Polycythemia vera occurs when too...

hematologic malignancies

Preclinical Study Identifies Potential Drug Combination for Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

Combining the molecular targeted drug ibrutinib (Imbruvica) with the investigational anticancer agent ABT-199 may improve outcomes for patients with mantle cell lymphoma and chronic lymphocytic leukemia (CLL), according to preclinical data presented at the American Association for Cancer Research...

hematologic malignancies

Preclinical Study Looks at RNA Polymerase I Inhibitor in Refractory AML and Multiple Myeloma

A laboratory study of the investigational drug CX-5461, which blocks the inhibition of RNA polymerase I transcription, has found that it prolonged survival in mouse models of highly aggressive acute myeloid leukemia (AML) and multiple myeloma refractory to standard therapy. In addition, the...

hematologic malignancies

FDA Grants Fast Track Designation to Novel JAK2 Inhibitor for the Treatment of Myelofibrosis

The U.S. Food and Drug Administration has granted Fast Track designation to pacritinib for the treatment of intermediate- and high-risk myelofibrosis, including patients with disease-related thrombocytopenia on other JAK2 therapy or patients who are intolerant to or whose symptoms are suboptimally...

hematologic malignancies
leukemia
myelodysplastic syndromes

Past Exposure to Thiopurines Associated With Increased Risk of Myeloid Disorders in Patients With Inflammatory Bowel Disease

Past exposure to immunosuppressive drugs called thiopurines has been found to increase the risk of myeloid disorders, such as acute myeloid leukemia and myelodysplastic syndrome, among patients with inflammatory bowel disease (IBD). The findings were reported by Lopez et al in Clinical...

Advertisement



Advertisement


Advertisement